Why Baseimmune’s IPF entry challenges a decade of single-target failure in pulmonary fibrosis
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
